Role of PET in medullary thyroid carcinoma.

Details

Serval ID
serval:BIB_31538D0DBF3C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Role of PET in medullary thyroid carcinoma.
Journal
Minerva endocrinologica
Author(s)
Rufini V., Treglia G., Perotti G., Leccisotti L., Calcagni M.L., Rubello D.
ISSN
0391-1977 (Print)
ISSN-L
0391-1977
Publication state
Published
Issued date
06/2008
Peer-reviewed
Oui
Volume
33
Number
2
Pages
67-73
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
In the diagnostic assessment of medullary thyroid carcinoma (MTC), nuclear medicine imaging provides its contribution mainly in the postoperative work-up to detect residual or recurrent tumor. With respect to scintigraphy with gamma-emitter radiopharmaceuticals, positron emission tomography (PET) offers interesting perspectives owing to its higher image quality, spatial resolution and speed. Moreover, the recent developments of hybrid machines allow to obtain images that simultaneously hold both anatomic (computed tomography) and functional (PET) information with great impact on diagnostic efficacy. (18)F-fluoro-deoxyglucose ((18)F-FDG) is the most frequently used PET tracer in oncology. Preliminary reports of FDG-PET in MTC patients show encouraging results with a higher sensitivity in detecting local recurrent and metastatic disease when compared with single photon emission tracers. However, (18)F-FDG uptake depends on lesion size and to some extent on the grade of differentiation and biologic aggressiveness of the tumor; so FDG-PET seems useful mainly in patients with very high calcitonin levels and high progression rate. Like other neuroendocrine tumors, MTC is characterized by the presence of amine uptake mechanism and/or peptide receptors at the cell membrane allowing the clinical use of specific radiopharmaceuticals that reflect the different metabolic pathways of MTC, and in particular the synthesis, storage and release of hormones ((18)F-dihydroxyphenilalanine, (18)F-DOPA and (18)F-fluorodopamine, (18)F-FDA) and the expression of receptors ((68)Ga-labeled somatostatin analogs). These tracers are currently under investigation and will further improve the diagnostic approach of MTC.

Keywords
Carcinoma, Medullary/diagnostic imaging, Fluorodeoxyglucose F18, Humans, Positron-Emission Tomography/methods, Radiopharmaceuticals, Reproducibility of Results, Sensitivity and Specificity, Thyroid Neoplasms/diagnostic imaging
Pubmed
Web of science
Create date
20/08/2017 21:23
Last modification date
20/08/2019 13:16
Usage data